249 related articles for article (PubMed ID: 32062650)
1. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
[TBL] [Abstract][Full Text] [Related]
4. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
[TBL] [Abstract][Full Text] [Related]
5. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
6. Influence of the pH Value of Refluxate and Proximal Extent on Heartburn Perception in Patients with Proton Pump Inhibitor-Refractory Non-Erosive Reflux Disease.
Abe Y; Koike T; Saito M; Okata T; Norita K; Kikuchi H; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Shimosegawa T; Masamune A
Digestion; 2020; 101(4):375-381. PubMed ID: 31357199
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
Kohata Y; Fujiwara Y; Yamagami H; Tanigawa T; Shiba M; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
[TBL] [Abstract][Full Text] [Related]
11. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Hoshino S; Kawami N; Takenouchi N; Umezawa M; Hanada Y; Hoshikawa Y; Kawagoe T; Sano H; Hoshihara Y; Nomura T; Iwakiri K
Digestion; 2017; 95(2):156-161. PubMed ID: 28190016
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of endoluminal gastroplication in Japanese patients with proton pump inhibitor-resistant, non-erosive esophagitis.
Tokudome K; Funaki Y; Sasaki M; Izawa S; Tamura Y; Iida A; Ogasawara N; Konagaya T; Tokura Y; Kasugai K
World J Gastroenterol; 2012 Nov; 18(41):5940-7. PubMed ID: 23139611
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms.
Hoshikawa Y; Hoshino S; Kawami N; Iwakiri K
J Gastroenterol; 2021 Feb; 56(2):117-124. PubMed ID: 33247348
[TBL] [Abstract][Full Text] [Related]
16. Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs.
Tanaka H; Takeuchi T; Nishida S; Hongo H; Takii M; Higashino T; Sanomura M; Miyazaki H; Hoshimoto M; Kimura T; Sakaguchi M; Abe T; Hakoda A; Sugawara N; Iwatsubo T; Kawaguchi S; Ota K; Kojima Y; Higuchi K
Digestion; 2023; 104(4):270-282. PubMed ID: 36649678
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
[TBL] [Abstract][Full Text] [Related]
18. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
Shi Y; Tan N; Zhang N; Xiong L; Peng S; Lin J; Chen M; Xiao Y
Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.
Asaoka D; Nagahara A; Hojo M; Matsumoto K; Ueyama H; Matsumoto K; Izumi K; Takeda T; Komori H; Akazawa Y; Shimada Y; Osada T; Watanabe S
Biomed Rep; 2017 Feb; 6(2):175-180. PubMed ID: 28357069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
